Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.06.030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Ying-Hao Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science & Biotechnology, Heilongjiang Bayi Agricultural University, Daqing, 163319, China. Electronic address: hyhbynd@163.com. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Fatty Liver, Alcoholic, Metabolic Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Education, Korea Research Institute of Bioscience and Biotechnology, National Research Foundation of Korea.
Abstract (Originalsprache)
Lipid droplets are unique lipid storage organelles in hepatocytes. Lipophagy is a key mechanism of selective degradation of lipid droplets through lysosomes. It plays a crucial role in the prevention of metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), and is a potential therapeutic target for treating these dysfunctions. In this review, we highlighted recent research and discussed advances in key proteins and molecular mechanisms related to lipophagy in liver disease. Reactive oxygen species (ROS) is an inevitable product of metabolism in alcohol-treated or high-fat-treated cells. Under this light, the potential role of ROS in autophagy in lipid droplet removal was initially explored to provide insights into the link between oxidative stress and metabolic liver disease. Subsequently, the current measures and drugs that treat NAFLD and AFLD through lipophagy regulation were summarized. The complexity of molecular mechanisms underlying lipophagy in hepatocytes and the need for further studies for their elucidation, as well as the status and limitations of current therapeutic measures and drugs, were also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Science & Biotechnology, Heilongjiang Bayi Agricultural University, Daqing, 163319, China. Electronic address: hyhbynd@163.com.
- College of Life Science & Biotechnology, Heilongjiang Bayi Agricultural University, Daqing, 163319, China.
- College of Life Science & Biotechnology, Heilongjiang Bayi Agricultural University, Daqing, 163319, China. Electronic address: sunhunan76@163.com.
- Primate Resources Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Jeonbuk, 56216, Republic of Korea; Department of Functional Genomics, KRIBB School of Bioscience, University of Science and Tec…
Förderung
- Ministry of Education
- Korea Research Institute of Bioscience and Biotechnology
- National Research Foundation of Korea
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Han, Y. H., He, X. M., Jin, M. H., Sun, H. N., & Kwon, T. (2023). Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.06.030
Vancouver
Han YH, He XM, Jin MH, Sun HN, Kwon T. Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.06.030
BibTeX
@article{Han2023,
author = {Han, Ying-Hao and He, Xin-Mei and Jin, Mei-Hua and Sun, Hu-Nan and Kwon, Taeho},
title = {Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.06.030}
}
EUVIMED